> A major study underscores that tamoxifen cuts the incidence of breast cancer almost in half among women at risk of the disease. Perhaps most amazingly, a majority of the women offered the drug turned it down, citing concerns about potential side effects or alternatives. Report
> Adherex Technologies said that it will move eniluracil for enhancing chemotherapy into late-stage trials by mid-2007. Release
> FDA staffers said that Novartis has not presented data demonstrating that its experimental transplant drug Certican is safe and effective. Report
> AmpliMed of Tucson, AZ, has announced positive preliminary Phase I data for its lead drug candidate, Amplimexon, in patients with advanced solid tumors. Release
> ARIAD Pharmaceuticals said that interim results for a Phase II trial of its mTOR inhibitor, AP23573, demonstrated that 27 percent of 188 evaluable patients treated with AP23573 had sustained tumor regression and/or disease stabilization. Release
> A new study from Stanford asserts that antidepressants may be misused in treating adolescents. Article
> OXiGENE said that preclinical data indicates the combination of CA4P or OXi4503 with the anti-angiogenic drug, Avastin, could offer a powerful and highly targeted treatment strategy for fighting solid tumors. Release
And Finally… A large number of young adults in America get their prescription drugs from friends. They say it makes sense. Doctors say it's plain dangerous. Article